Quality-of-life assessment in French patients with metastatic melanoma in real life
Marguerite Kandel
(1, 2)
,
Stéphane Dalle
(3)
,
Aurélie Bardet
(1, 2, 4)
,
Clara Allayous
(5)
,
Laurent Mortier
(6)
,
Caroline Dutriaux
(7)
,
Bernard Guillot
(8)
,
Marie Thérèse Leccia
(9)
,
Sophie Dalac
(10)
,
Délphine Legoupil
(11)
,
Phillippe Saiag
(12)
,
Henri Montaudie
(13)
,
Jean Philippe Arnault
(14)
,
Florence Brunet-Possenti
(15)
,
Jean Jacques Grob
(16)
,
Julie Dequatrebarbes
(17)
,
Marie Beylot-Barry
(18)
,
Thierry P. Lesimple
(19)
,
François F. Aubin
(20)
,
Eve Maubec
(21)
,
Florence Granel-Brocard
(22)
,
Pierre Emmanuel Stoebner
(23)
,
Alain Dupuy
(24)
,
Brigitte Dreno
(25)
,
Stefan Michiels
(1, 2, 4, 26)
,
Célèste Lebbe
(27)
,
Isabelle Borget
(1, 2, 28, 4)
1
UVSQ -
Université de Versailles Saint-Quentin-en-Yvelines
2 IGR - Institut Gustave Roussy
3 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
4 SBE - Service de biostatistique et d'épidémiologie
5 HIPI (UMR_S_976 / U976) - Immunologie humaine, physiopathologie & immunothérapie
6 OncoThAI - Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189
7 Groupe hospitalier Saint-André
8 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
9 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
10 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
11 CHRU Brest - Centre Hospitalier Régional Universitaire de Brest
12 Hôpital Ambroise Paré [AP-HP]
13 CHU Nice - Centre Hospitalier Universitaire de Nice
14 Service de dermatologie [CHU d'Amiens-Picardie]
15 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
16 Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM]
17 Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
18 Service de dermatologie [Bordeaux]
19 CRLCC - CRLCC Eugène Marquis
20 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
21 Avicennes University Hospital
22 Service de Dermatologie et Allergologie [CHRU Nancy]
23 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
24 Service de Dermatologie [Rennes] = Dermatology [Rennes]
25 Service de dermatologie [Nantes]
26 U1018 (Équipe 2) - Oncostat
27 Centre Léon Bérard [Lyon]
28 AP-HP. Université Paris Saclay
2 IGR - Institut Gustave Roussy
3 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
4 SBE - Service de biostatistique et d'épidémiologie
5 HIPI (UMR_S_976 / U976) - Immunologie humaine, physiopathologie & immunothérapie
6 OncoThAI - Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189
7 Groupe hospitalier Saint-André
8 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
9 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
10 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
11 CHRU Brest - Centre Hospitalier Régional Universitaire de Brest
12 Hôpital Ambroise Paré [AP-HP]
13 CHU Nice - Centre Hospitalier Universitaire de Nice
14 Service de dermatologie [CHU d'Amiens-Picardie]
15 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
16 Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM]
17 Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
18 Service de dermatologie [Bordeaux]
19 CRLCC - CRLCC Eugène Marquis
20 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
21 Avicennes University Hospital
22 Service de Dermatologie et Allergologie [CHRU Nancy]
23 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
24 Service de Dermatologie [Rennes] = Dermatology [Rennes]
25 Service de dermatologie [Nantes]
26 U1018 (Équipe 2) - Oncostat
27 Centre Léon Bérard [Lyon]
28 AP-HP. Université Paris Saclay
Marguerite Kandel
Connectez-vous pour contacter l'auteur
- Fonction : Auteur correspondant
- PersonId : 1098896
Connectez-vous pour contacter l'auteur
Stéphane Dalle
- Fonction : Auteur
- PersonId : 937229
- IdHAL : stephanedalle
- ORCID : 0000-0002-3423-4548
- IdRef : 075987279
Laurent Mortier
- Fonction : Auteur
- PersonId : 793850
- ORCID : 0000-0002-2644-1790
Bernard Guillot
- Fonction : Auteur
- PersonId : 760319
- ORCID : 0000-0001-6139-4136
Sophie Dalac
- Fonction : Auteur
- PersonId : 762781
- ORCID : 0000-0002-9101-3119
Florence Brunet-Possenti
- Fonction : Auteur
- PersonId : 1101822
- ORCID : 0000-0003-2100-2913
- IdRef : 25296456X
Marie Beylot-Barry
- Fonction : Auteur
- PersonId : 762790
- ORCID : 0000-0001-6150-1229
- IdRef : 05956427X
Stefan Michiels
- Fonction : Auteur
- PersonId : 759812
- IdHAL : stefan-michiels
- ORCID : 0000-0002-6963-2968
- IdRef : 129474622
Résumé
Background: Significant progress was recently observed in the treatment of metastatic melanoma (MM). With >50% of patients now reaching a second line of treatment and a significant improvement in the survival rate, an assessment of quality of life (QoL) during the whole course of the disease becomes necessary. The objective of this study was to describe the QoL of patients with MM in France, from their diagnosis of advanced disease to their death, in real life. Methods: QoL data were collected through MelBase, a prospective, French, multicentric cohort dedicated to the follow-up of adults with MM. QoL was assessed using the EuroQoL-5D questionnaire and the Functional Assessment of Cancer Treatment (FACT)-Melanoma questionnaire at the time of study inclusion, every 3 months, and at the time of each treatment change until death. To assess longitudinal changes from baseline to death, mixed-effect models for repeated-measures analyses were used to control for baseline covariates. Results: QoL was assessed in 1435 patients who were included in the study between 2013 and 2018. The median follow-up was 9.4 months, and 47% of patients died during follow-up. During first-line treatment, the model-based, mean utility score was 0.830 (95% CI, 0.818-0.843), the mean FACT-General score was 77.22 (95% CI, 76.23-78.22), and the mean FACT-Melanoma score was 129.46 (95% CI, 128.02-130.90). At the time of a change in treatment line, there was a decrease of −0.027 (95% CI, −0.03, −0.02) in the utility score, −1.82 (95% CI, −1.88, −1.76) in the FACT-General score, and −2.98 (95% CI, −3.05, −2.91) in the FACT-Melanoma score compared with first-line treatment. Conclusions: In the MelBase cohort, the QoL among patients with MM seems to be fairly stable over the whole disease course, although a small but significant decrease at time therapy is changed is observed.
Format du dépôt | Notice |
---|---|
Type de dépôt | Article dans une revue |
Titre |
en
Quality-of-life assessment in French patients with metastatic melanoma in real life
|
Résumé |
en
Background: Significant progress was recently observed in the treatment of metastatic melanoma (MM). With >50% of patients now reaching a second line of treatment and a significant improvement in the survival rate, an assessment of quality of life (QoL) during the whole course of the disease becomes necessary. The objective of this study was to describe the QoL of patients with MM in France, from their diagnosis of advanced disease to their death, in real life. Methods: QoL data were collected through MelBase, a prospective, French, multicentric cohort dedicated to the follow-up of adults with MM. QoL was assessed using the EuroQoL-5D questionnaire and the Functional Assessment of Cancer Treatment (FACT)-Melanoma questionnaire at the time of study inclusion, every 3 months, and at the time of each treatment change until death. To assess longitudinal changes from baseline to death, mixed-effect models for repeated-measures analyses were used to control for baseline covariates. Results: QoL was assessed in 1435 patients who were included in the study between 2013 and 2018. The median follow-up was 9.4 months, and 47% of patients died during follow-up. During first-line treatment, the model-based, mean utility score was 0.830 (95% CI, 0.818-0.843), the mean FACT-General score was 77.22 (95% CI, 76.23-78.22), and the mean FACT-Melanoma score was 129.46 (95% CI, 128.02-130.90). At the time of a change in treatment line, there was a decrease of −0.027 (95% CI, −0.03, −0.02) in the utility score, −1.82 (95% CI, −1.88, −1.76) in the FACT-General score, and −2.98 (95% CI, −3.05, −2.91) in the FACT-Melanoma score compared with first-line treatment. Conclusions: In the MelBase cohort, the QoL among patients with MM seems to be fairly stable over the whole disease course, although a small but significant decrease at time therapy is changed is observed.
|
Auteur(s) |
Marguerite Kandel
1, 2
, Stéphane Dalle
3
, Aurélie Bardet
1, 2, 4
, Clara Allayous
5
, Laurent Mortier
6
, Caroline Dutriaux
7
, Bernard Guillot
8
, Marie Thérèse Leccia
9
, Sophie Dalac
10
, Délphine Legoupil
11
, Phillippe Saiag
12
, Henri Montaudie
13
, Jean Philippe Arnault
14
, Florence Brunet-Possenti
15
, Jean Jacques Grob
16
, Julie Dequatrebarbes
17
, Marie Beylot-Barry
18
, Thierry P. Lesimple
19
, François F. Aubin
20
, Eve Maubec
21
, Florence Granel-Brocard
22
, Pierre Emmanuel Stoebner
23
, Alain Dupuy
24
, Brigitte Dreno
25
, Stefan Michiels
1, 2, 4, 26
, Célèste Lebbe
27
, Isabelle Borget
1, 2, 28, 4
1
UVSQ -
Université de Versailles Saint-Quentin-en-Yvelines
( 81173 )
- 55 avenue de Paris - 78035 Versailles cedex
- France
2
IGR -
Institut Gustave Roussy
( 156104 )
- 114, rue Édouard-Vaillant 94805 Villejuif Cedex -France
- France
3
UNICANCER/CRCL -
Centre de Recherche en Cancérologie de Lyon
( 139829 )
- 28, rue Laennec - 69373 Lyon
- France
4
SBE -
Service de biostatistique et d'épidémiologie
( 59772 )
- Gustave Roussy. 114, rue Édouard-Vaillant. 94805 Villejuif Cedex - France
- France
5
HIPI (UMR_S_976 / U976) -
Immunologie humaine, physiopathologie & immunothérapie
( 1005003 )
- "Hôpital Saint Louis - Pavillon Bazin
1 avenue Claude Vellefaux
75010 Paris"
- France
6
OncoThAI -
Thérapies Assistées par Lasers et Immunothérapies pour l'Oncologie - U 1189
( 489340 )
- OncoThAI - Faculté de Médecine - 1 avenue Oscar Lambret
- 59037 Lille Cedex.
- France
7
Groupe hospitalier Saint-André
( 301274 )
-
- France
8
CHRU Montpellier -
Centre Hospitalier Régional Universitaire [Montpellier]
( 258773 )
- 191 avenue du doyen Gaston Giraud 34295 Montpellier
- France
9
CHUGA -
Centre Hospitalier Universitaire [CHU Grenoble]
( 257328 )
- CS 10217
38043 Grenoble cedex 9
- France
10
CHU Dijon -
Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
( 300924 )
- CHU Dijon - 14 rue Paul Gaffarel - 21079 Dijon
- France
11
CHRU Brest -
Centre Hospitalier Régional Universitaire de Brest
( 356603 )
- France
12
Hôpital Ambroise Paré [AP-HP]
( 300151 )
- 9, avenue Charles de Gaulle92104 Boulogne-Billancourt cedex
- France
13
CHU Nice -
Centre Hospitalier Universitaire de Nice
( 300113 )
- 30, Voie Romaine
CS 51069 - 06001 Nice Cedex 1
- France
14
Service de dermatologie [CHU d'Amiens-Picardie]
( 523573 )
- CHU Amiens-Picardie
80054 Amiens Cedex 1
- France
15
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
( 300156 )
- 46 Rue Henri Huchard, 75018 Paris
- France
16
Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM]
( 443266 )
- Hôpital de la Timone
264 rue Saint Pierre
13885 Marseille
- France
17
Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
( 447517 )
- Chemin du Loup BP 14110
74164 Saint-Julien-en-Genevois Cedex
- France
18
Service de dermatologie [Bordeaux]
( 11173 )
- Avenue Magellan 33500 MERIGNAC
- France
19
CRLCC -
CRLCC Eugène Marquis
( 301510 )
- Avenue Bataille Flandres-Dunkerque 35042 RENNES CEDEX
- France
20
CHRU Besançon -
Centre Hospitalier Régional Universitaire de Besançon
( 300165 )
- 3, boulevard A. Fleming - 25030 Besançon Cedex
- France
21
Avicennes University Hospital
( 352771 )
-
- France
22
Service de Dermatologie et Allergologie [CHRU Nancy]
( 84553 )
- 36 Quai de la Bataille 54000 Nancy
- France
23
CHU Nîmes -
Centre Hospitalier Universitaire de Nîmes
( 361498 )
- 4 Rue du Professeur Robert Debré, 30029 Nîmes
- France
24
Service de Dermatologie [Rennes] = Dermatology [Rennes]
( 215996 )
- CHU Rennes, 2 Rue Henri le Guilloux, 35000 Rennes
- France
25
Service de dermatologie [Nantes]
( 115118 )
- France
26
U1018 (Équipe 2) -
Oncostat
( 1051100 )
- Gustave Roussy.
114 rue Édouard Vaillant, 94805 Villejuif Cedex
- France
27
Centre Léon Bérard [Lyon]
( 20549 )
- 28, rue Laennec 69373 LYON Cedex 08
- France
28
AP-HP. Université Paris Saclay
( 1066727 )
- France
|
Langue du document |
Anglais
|
Nom de la revue |
|
Vulgarisation |
Non
|
Comité de lecture |
Oui
|
Audience |
Internationale
|
Date de publication |
2020
|
Volume |
126
|
Numéro |
3
|
Page/Identifiant |
611-618
|
Domaine(s) |
|
Mots-clés (Mesh) |
|
Financement |
|
Mots-clés |
en
Clinical practice, Immunotherapy, Metastatic melanoma, Quality of life, Real-life, Targeted therapy
|
DOI | 10.1002/cncr.32554 |
Pubmed Id | 31639198 |
Loading...